Transfusion medicine

Department of Defense Approves $4.9M for Next Phase Traumatic Brain Injury Study Using Hope Biosciences’ Stem Cells

Retrieved on: 
Thursday, June 1, 2023
Research, Contracts, Neurology, Clinical Trials, Health Technology, Stem Cells, Biotechnology, Health, Science, Defense, Critical care, Naval academy, Friends, George, McGovern Medical School, Clinical trial, Woman, TBI, Veteran, Microsoft Exchange Server, HB, Hope, MD, Traumatic brain injury, Pediatrics, Department of Defense Serum Repository, Transfusion medicine, University of Texas Health Science Center at Houston, Centers for Disease Control and Prevention, FDA, Conference, Safety, Complex, Nursing, Pharmaceutical industry, Trauma, Neuroscience

The award is a significant positive step toward developing treatment for a currently incurable condition that affects approximately 1.5 million Americans every year, killing 50,000 annually.

Key Points: 
  • The award is a significant positive step toward developing treatment for a currently incurable condition that affects approximately 1.5 million Americans every year, killing 50,000 annually.
  • Donna Chang, CEO of Hope Biosciences, highlighted the significance of their technology, stating, “Our repeatable stem cell therapy offers scalability, affordability and rapid delivery over one’s lifetime.
  • “Receipt of federal funding for research using Hope Biosciences’ stem cells is a deeply personal occasion,” reflects Jan Shultis, a Naval Academy graduate who joined the team at Hope Biosciences after thirteen years in uniform.
  • “TBI is part of my story, and that of scores of family members and friends who served.

QuidelOrtho to Participate in William Blair 43rd Annual Growth Stock Conference

Retrieved on: 
Tuesday, May 23, 2023
Medical Supplies, Health, Hospitals, Health Technology, Pharmaceutical, Biotechnology, William Blair & Company, Conference, Transfusion medicine, Medical device, Management

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the William Blair 43rd Annual Growth Stock Conference in Chicago, Illinois, on June 6, 2023.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the William Blair 43rd Annual Growth Stock Conference in Chicago, Illinois, on June 6, 2023.
  • A presentation will be given by Douglas Bryant, President and Chief Executive Officer, and Joseph Busky, Chief Financial Officer, scheduled for 2:00 p.m. CT/12:00 p.m. PT.

Life Science Instrumentation Market worth $73.9 billion | MarketsandMarkets

Retrieved on: 
Friday, May 12, 2023
Allergy, Antigen, Food, GC/MS, Immunogenetics, Health, Genetics, HLA, Transfusion medicine, Allele, NGS, Shimadzu, Personalized medicine, AB, Thermo Fisher Scientific, Element, Danaher Corporation, Science, Patient, Risk, Organ transplantation, Algorithm, Immune system, Cancer, Medicine, Agilent Technologies, Diagnosis, Waters Corporation, Research, LC/MS, Mindful Scientific Inc., Safety, Dentistry, Vaccine, Medical imaging

Life Science Instrumentation Market Advantages:

Key Points: 
  • Life Science Instrumentation Market Advantages:
    Improved Organ Transplantation Success: Accurate Life Science Instrumentation plays a critical role in organ transplantation.
  • Rapid Technological Advancements: The Life Science Instrumentation market benefits from ongoing technological advancements, such as next-generation sequencing (NGS), high-resolution molecular techniques, and advanced data analysis algorithms.
  • Overall, the Life Science Instrumentation market offers significant advantages, including improved organ transplantation outcomes, personalized medicine approaches, enhanced disease diagnosis and treatment, advancements in transfusion medicine, scientific research opportunities, and rapid technological progress.
  • These advantages contribute to the growing importance and widespread utilization of Life Science Instrumentation in the field of healthcare.

Life Science Instrumentation Market worth $73.9 billion | MarketsandMarkets

Retrieved on: 
Friday, May 12, 2023
Allergy, Antigen, Food, GC/MS, Immunogenetics, Health, Genetics, HLA, Transfusion medicine, Allele, NGS, Shimadzu, Personalized medicine, AB, Thermo Fisher Scientific, Element, Danaher Corporation, Science, Patient, Risk, Organ transplantation, Algorithm, Immune system, Cancer, Medicine, Agilent Technologies, Diagnosis, Waters Corporation, Research, LC/MS, Mindful Scientific Inc., Safety, Dentistry, Vaccine, Medical imaging

Life Science Instrumentation Market Advantages:

Key Points: 
  • Life Science Instrumentation Market Advantages:
    Improved Organ Transplantation Success: Accurate Life Science Instrumentation plays a critical role in organ transplantation.
  • Rapid Technological Advancements: The Life Science Instrumentation market benefits from ongoing technological advancements, such as next-generation sequencing (NGS), high-resolution molecular techniques, and advanced data analysis algorithms.
  • Overall, the Life Science Instrumentation market offers significant advantages, including improved organ transplantation outcomes, personalized medicine approaches, enhanced disease diagnosis and treatment, advancements in transfusion medicine, scientific research opportunities, and rapid technological progress.
  • These advantages contribute to the growing importance and widespread utilization of Life Science Instrumentation in the field of healthcare.

NYBC Ventures Launches $50M Fund to Accelerate Innovations in Blood and Cellular Therapies

Retrieved on: 
Thursday, May 11, 2023
Research, Clinical Trials, Stem Cells, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Therapy, Transfusion medicine, Infection, General partnership, Organization, Venture, M.D, New York Blood Center, Blood, MPH, Pharmaceutical industry, Health care

NYBC Ventures , today announced the launch of its inaugural fund with a $50 million investment from New York Blood Center, Inc. (NYBC) to accelerate innovation in blood-related fields, and cellular therapies and enabling technologies.

Key Points: 
  • NYBC Ventures , today announced the launch of its inaugural fund with a $50 million investment from New York Blood Center, Inc. (NYBC) to accelerate innovation in blood-related fields, and cellular therapies and enabling technologies.
  • NYBC Ventures is an early-stage life sciences investment fund that will focus on investment in therapeutics, devices, and innovative technologies addressing the most pressing challenges in benign hematology, transfusion medicine, and infectious disease.
  • “This is the first venture fund solely dedicated to advancing innovation in blood and cell-based therapies and technologies,” said Christopher D. Hillyer, M.D., President and CEO, New York Blood Center Inc.; General Partner, NYBC Ventures.
  • NYBC Ventures employs a model of patient capital and takes a flexible approach to financing vehicles and structures.

QuidelOrtho Reports First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 3, 2023
Technology, Medical Devices, Hospitals, Health Technology, Biotechnology, Health, Data Management, Other Science, Science, Transfusion medicine, QuidelOrtho, GAAP, Interest, EBITDA, Webcast, Growth, EPS, Conference, Automation, Medical device, Video game, Online shopping

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the first quarter ended April 2, 2023.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the first quarter ended April 2, 2023.
  • The following discussion of financial results is based on supplemental combined information:
    First quarter 2023 total revenue of $846.1 million decreased by 44% in constant currency, compared to $1,502.4 million for the first quarter of 2022.
  • The Company will provide 2023 financial guidance during its financial results conference call today.
  • ET to discuss its financial results for the first quarter ended April 2, 2023.

LABCORP AND JEFFERSON HEALTH ANNOUNCE STRATEGIC LABORATORY RELATIONSHIP

Retrieved on: 
Wednesday, May 3, 2023
HLA, Transfusion medicine, Teaching, Thomas Jefferson University, Pathology, LH, Research, Jefferson Health, Patient, Flow cytometry, Autoimmune disease, IDEA, Health, Neurology, NYSE, Pharmaceutical industry, Nursing, MD, Labcorp

BURLINGTON, N.C., May 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced an agreement to enter into a strategic relationship with Jefferson Health (Jefferson), the largest health system serving the greater Philadelphia area and Southern New Jersey. When complete, the arrangements between Jefferson and Labcorp will serve to build academic collaborations around teaching and the development of innovative tests.

Key Points: 
  • BURLINGTON, N.C., May 3, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced an agreement to enter into a strategic relationship with Jefferson Health (Jefferson), the largest health system serving the greater Philadelphia area and Southern New Jersey.
  • Jefferson and Labcorp will work together to establish the Innovation Driving Excellence in Academics (IDEA) initiative, with a goal of advancing testing capabilities and technologies to improve health outcomes.
  • "This strategic relationship enables Jefferson to leverage Labcorp's wide-range of laboratory services, which will help deliver improved outcomes for our patients and optimal service to providers," said Joseph G. Cacchione, MD, CEO, Jefferson.
  • This relationship follows other strategic collaborations that Labcorp has established with a range of local and regional health systems that have enhanced services for patients and providers.

Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference

Retrieved on: 
Monday, May 1, 2023
Science, Neurology, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, San Francisco, Critical care, University, Novel Therapeutic Targets for Antiarrhythmic Drugs, AABB, Critical, Colorado State University, Stroke, University of California, San Francisco, TBI, Regenerative medicine, DOD, DARPA, Patient, Blood, Transfusion medicine, FDA, SCI, Therapy, BARDA, NIH, Pharmaceutical industry, Medical device, Trauma, Polytrauma

Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics in Trauma and Critical Care’s (CTTACC) conference, “Cellular Therapies and Transfusion Medicine in Trauma and Critical Care,” from May 8-11, 2023 in Scottsdale, Arizona.

Key Points: 
  • Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics in Trauma and Critical Care’s (CTTACC) conference, “Cellular Therapies and Transfusion Medicine in Trauma and Critical Care,” from May 8-11, 2023 in Scottsdale, Arizona.
  • Presented by the University of California San Francisco and Colorado State University, this conference is the fifth in a series of conferences supporting the development and translation of novel therapies in trauma and critical care medicine, a field with limited therapeutic options.
  • This conference will bring together the expertise and input of cell therapy companies, clinicians, basic scientists, industry, FDA, NIH, AABB, DARPA, BARDA and DOD representatives to discuss current research and existing barriers in the translation of these novel therapies in trauma and critical care medicine.
  • Dr. Willie Mays, Executive Vice President and Head of Regenerative Medicine and Neuroscience Programs, has been invited to participate in this conference.

EQS-News: STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2023 AND CONFIRMS FINANCIAL GUIDANCE

Retrieved on: 
Friday, April 28, 2023
Sepsis, Community Research and Development Information Service, Transfusion medicine, Annual, Tax, Service parts pricing, Magazine, AGM, EBIT, Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science, Development, PIN, CEST, Flow cytometry, SE, Growth, Death, US FDA, Retail, Pharmaceutical industry, Clothing

Adjusted EBIT stood at € 3.8 million in the first quarter of 2023, compared with € 15.0 million in the previous year’s quarter.

Key Points: 
  • Adjusted EBIT stood at € 3.8 million in the first quarter of 2023, compared with € 15.0 million in the previous year’s quarter.
  • On this basis, and taken together with the performance in line with expectations in the first quarter of 2023 and further growth in sales contributions from new product launches, STRATEC can confirm its financial guidance for the 2023 financial year.
  • Together with its partners, STRATEC pressed further ahead with numerous development projects in the first quarter of 2023.
  • The STRATEC Group’s workforce continued to grow and passed the 1,500 mark for the first time in the first quarter of 2023.

MAK-SYSTEM ANNOUNCES STRATEGIC RELATIONSHIP WITH AWS FOR THE LAUNCH OF MAK.care

Retrieved on: 
Tuesday, April 25, 2023
New Zealand Blood Service, Patient blood management, Amazon Web Services, Service, Transfusion medicine, Health care, Privacy, Patient, Risk, Blood, CIO, AI, New York Blood Center, AWS, Service-level agreement, Safety, Pharmaceutical industry, Medical device

We are thrilled to be collaborating with AWS to bring our cutting-edge MAK.care platform to the global market," said Frank Jaubert, CEO of MAK-System.

Key Points: 
  • We are thrilled to be collaborating with AWS to bring our cutting-edge MAK.care platform to the global market," said Frank Jaubert, CEO of MAK-System.
  • "We see many opportunities from the introduction of MAK.care", added Dr Giulio Bognolo, MAK-System Chief Product Officer & Chief Medical Officer.
  • Our joint initiative with AWS will provide the reassurance of an available, secure, and reliable technology platform to support the customer's business.
  • "We are pleased to be working with MAK-System on this strategic initiative," said Jens Dommel, AWS Head of Healthcare for EMEA.